Last reviewed · How we verify
ADH -1 and carboplatin
Antiangiogenic and platinum-based chemotherapy
Antiangiogenic and platinum-based chemotherapy Used for Non-small cell lung cancer.
At a glance
| Generic name | ADH -1 and carboplatin |
|---|---|
| Sponsor | Adherex Technologies, Inc. |
| Drug class | Angiogenesis inhibitor and platinum-based chemotherapy |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ADH-1 is an angiogenesis inhibitor that works by targeting vascular endothelial growth factor (VEGF), while carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication.
Approved indications
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADH -1 and carboplatin CI brief — competitive landscape report
- ADH -1 and carboplatin updates RSS · CI watch RSS
- Adherex Technologies, Inc. portfolio CI